Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer.
The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding a liver tumor using a radiopaque bead which can be seen on CT scans.
Get the full story at our sister site, Drug Delivery Business News.